I-Mab - ADR

NASDAQ:IMAB   12:25:38 PM EDT
79.98
+0.99 (+1.25%)
Products, Regulatory

I-Mab Announces First Patient Dosed In China Phase 2 Combination Trial Of Lemzoparlimab

Published: 05/18/2021 12:23 GMT
I-Mab - ADR (IMAB) - I-mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab With Azacitidine in Patients With Acute Myeloid Leukemia Or Myelodysplastic Syndrome.
I-mab - Two U.S. Cohort Expansion Studies in Non-hodgkin Lymphoma, Advanced Solid Tumors on Track to Deliver Preliminary Topline Results by End 2021/early 2022.
I-mab - Patient Enrollment of Both Nhl and Solid Tumor Trials Will Be Completed by Q4 2021 With Preliminary Topline Data Expected Thereafter.